Differences in the Rates of Treatment of Severe Obesity Using Bariatric Surgery Across Socioeconomic Groups

A socioeconomic gradient in obesity, with greater prevalence observed in more disadvantaged groups, has been reported in most high-income countries.\(^2\) Severe obesity is a substantial and growing problem, affecting 1 in 7 Americans,\(^2\) and is associated with far greater adverse consequences relative to mild obesity (with a body mass index [BMI] of 30.0-34.9 [calculated as weight in kilograms divided by height in meters squared]). Lesser access to treatment for the severely obese in socioeconomically disadvantaged populations would risk further widening inequalities. Bariatric surgery is currently the only evidence-based option available that induces significant and sustained weight loss in severely obese patients.\(^3\) The present study aims to quantify the rates of treatment of severe obesity using bariatric surgery, according to the socioeconomic positions of severely obese Australian adults.

Methods | Customized data relating to all bariatric surgery episodes undertaken in Australian adults between July 2011 and June 2012 (n = 14,056) were obtained from the National Hospital Morbidity database and provided by the Australian Institute of Health and Welfare.\(^4\) Bariatric surgery episodes were selected based on 3 Australian Refined Diagnosis Related Groups codes (K04A-S, K04B-S, and K07Z-S). For privacy reasons, de-identified, aggregate data were provided to the research team by Medicare. This project was approved by the Deakin University Human Research and Integrity Board (project 2010-116). Customized data relating to the annual estimated number of adults with severe obesity in Australia were provided by the Australian Bureau of Statistics based on results from the nationally representative 2011-2012 Australian Health Survey.\(^5\) Weight status classifications were based on measured height and weight. All data were stratified by Index of Relative Socio-economic Disadvantage quintiles, an area-level measure of socioeconomic position (a lower quintile represents greater disadvantage).\(^5\)

Bariatric surgery rates were calculated as the observed annual number of bariatric surgery episodes divided by the estimated annual number of adults with severe obesity for each socioeconomic stratum in Australia (2011-2012). Severe obesity was defined as either class II (BMI = 35.0-39.9) or class III obesity (BMI ≥ 40.0) and represented the population potentially eligible to receive bariatric surgery. Equitable treatment across socioeconomic strata would be represented by roughly equal treatment rates.

The statistical significance of these comparisons was assessed using a z score and an associated P value. The z score was calculated as the difference between the annual treatment rate estimates divided by the standard error of this difference, with this standard error calculated as the square root of the sum of the squares of the individual annual treatment rate standard errors (Figure). Associated P values were derived using the standard normal probability distribution: quintile 5 vs quintile 4 (P = .25), quintile 5 vs quintile 3 (P = .17), quintile 5 vs quintile 2 (P < .001), and quintile 5 vs quintile 1 (P < .001).

<table>
<thead>
<tr>
<th>Socioeconomic Position, Index of Relative Socio-economic Disadvantage Quintiles</th>
<th>No. of Bariatric Surgery Episodes per 1000 People in Australian Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quintile 1 (least disadvantaged)</td>
<td>6.9 ± 1.1</td>
</tr>
<tr>
<td>Quintile 2</td>
<td>7.4 ± 1.1</td>
</tr>
<tr>
<td>Quintile 3</td>
<td>7.9 ± 1.1</td>
</tr>
<tr>
<td>Quintile 4</td>
<td>8.4 ± 1.1</td>
</tr>
<tr>
<td>Quintile 5 (most disadvantaged)</td>
<td>9.9 ± 1.1</td>
</tr>
</tbody>
</table>

Calculated as the observed number of bariatric surgery episodes or the number of Australian adults with severe obesity. Severe obesity was defined as either class II obesity (with a body mass index [BMI] of 35.0-39.9 [calculated as weight in kilograms divided by height in meters squared]) or class III obesity (BMI ≥ 40.0). The 95% CIs (error bars) reflect the variability in the survey estimates of population size. A lower socioeconomic position quintile reflects greater disadvantage. Data on the observed number of bariatric surgery episodes in Australia were obtained from the National Hospital Morbidity database,\(^4\) and data on the estimated number of people with severe obesity were obtained from the Australian Bureau of Statistics National Health Survey,\(^5\) 2011-2012.
Socioeconomic Disparities in Uterine Sarcoma Among Patients With Leiomyomata Undergoing Surgical Treatment

Uterine leiomyomata are one of the most common gynecologic problems among women in the United States, with an annual diagnosis range from 2.0 to 12.8 per 1000 reproductive-age women.1 Intervention is a standard management for symptomatic patients, and various procedures include open and laparoscopic hysterectomy, myolysis, uterine artery embolization, and magnetic resonance–guided focused ultrasound surgery.

The practice of electric morcellation has been used by gynecologic surgeons during laparoscopic and robotic-assisted hysterectomies and myomectomies as a less invasive alternative to open surgery.2 In April 2014, the US Food and Drug Administration (FDA) stated that they discouraged the use of this technique over concern that morcellation may spread unsuspected sarcoma tissue.3,4 Based on the literature, the FDA reported that 1 in 352 women have unsuspected uterine sarcoma while undergoing surgery for presumed benign leiomyoma.5 A recent study6 using an all-payer database found that 1 in 368 women who underwent morcellation had uterine cancer. However, the estimates in this study6 were lim-

Conflict of Interest Disclosures: Ms Keating previously received an independent research grant from Allergan Australia (funding years 2010-2011). No other disclosures are reported.

Funding/Support: This research was supported by an Australian Research Council (ARC) Linkage grant (LP120100418) and an Australian National Preventive Health Agency grant (188PE2E2011) and, in part, by the Victorian Government’s Operational Infrastructure Program. Dr Backholer was supported by a Postdoctoral Research Fellowship (PH 12M 6824) from the National Heart Foundation of Australia, an ARC Linkage grant (LP120100418), and an Australian National Preventive Health Agency grant (188PE2E2011). Dr Peeters was supported by a National Health and Medical Research Council Career Development Fellowship (1045456). Dr Stevenson was supported by an ARC Discovery Project grant (DP120103277). Drs Peeters and Moodie were supported by the National Health and Medical Research Council Centre for Research Excellence (grant 1041020).

Role of the Funder/Sponsor: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the Australian Bureau of Statistics and the Australian Institute of Health and Welfare for providing custom analyzed data. No compensation was provided to, or received from, the agencies providing data.


Population-Based Estimates of the Prevalence of Uterine Sarcoma Among Patients With Leiomyomata Undergoing Surgical Treatment

Uterine leiomyomata are one of the most common gynecologic problems among women in the United States, with an annual diagnosis range from 2.0 to 12.8 per 1000 reproductive-age women.1 Intervention is a standard management for symptomatic patients, and various procedures include open and laparoscopic hysterectomy, myolysis, uterine artery embolization, and magnetic resonance–guided focused ultrasound surgery.

The practice of electric morcellation has been used by gynecologic surgeons during laparoscopic and robotic-assisted hysterectomies and myomectomies as a less invasive alternative to open surgery.2 In April 2014, the US Food and Drug Administration (FDA) stated that they discouraged the use of this technique over concern that morcellation may spread unsuspected sarcoma tissue.3,4 Based on the literature, the FDA reported that 1 in 352 women have unsuspected uterine sarcoma while undergoing surgery for presumed benign leiomyoma.5 A recent study6 using an all-payer database found that 1 in 368 women who underwent morcellation had uterine cancer. However, the estimates in this study6 were lim-

Access to bariatric surgery for disadvantaged groups should be improved so that all members in society can benefit from this treatment. In Australia, this will most likely be achieved by increasing the funding allocated to bariatric surgery in public hospitals. Future research should examine the costs and benefits of bariatric surgery according to socioeconomic strata.

Catherine Keating, MPH
Kathryn Backholer, PhD
Marj Moodie, DrPH
Christopher Stevenson, PhD
Anna Peeters, PhD

Author Affiliations: Obesity and Population Health, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (Keating, Backholer, Moodie, Peeters); Deakin Health Economics, Deakin University, Melbourne, Australia (Keating, Moodie, Stevenson); School of Health and Social Development, Deakin University, Melbourne, Australia (Stevenson).

Corresponding Author: Catherine Keating, MPH, Obesity and Population Health, Baker IDI Heart and Diabetes Institute, Level 4, 99 Commercial Rd, Melbourne, Victoria, Australia 3004 (catherine.keating@bakeridi.edu.au).


Author Contributions: Ms Keating had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Keating, Backholer, Peeters. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Keating, Backholer. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Keating, Backholer, Stevenson. Obtained funding: Keating, Peeters. Study supervision: Moodie, Peeters.